Business Description
Adocia
ISIN : FR0011184241
Total Employee Number:
82Compare
Compare
Traded in other countries / regions
ADOC.FranceA89.Germany0QAI.UKADOCY.USA IPO Date
2016-04-08Description
Adocia is a clinical-stage biotechnology company. It specializes in the development of formulations of already approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. The firm has developed Biochaperone, a proprietary technology platform to enhance the effectiveness of therapeutic proteins. The company's clinical pipeline includes Biochaperone Lispro, Biochaparone Combo, Biochaparone Glucagon, and others. Its pre-clinical pipeline includes BioChaperone LisPram, BioChaperone Glargine GLP-1, and BioChaperone Glucagon GLP1. Its patent portfolio mainly consists of chronic wound healing, insulin therapy, and monoclonal antibodies.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.94 | |||||
Equity-to-Asset | 0.05 | |||||
Debt-to-Equity | 5.97 | |||||
Debt-to-EBITDA | -0.58 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -0.58 | |||||
Beneish M-Score | -5.25 | |||||
WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -61.4 | |||||
3-Year EBITDA Growth Rate | -24.5 | |||||
3-Year EPS without NRI Growth Rate | -10.1 | |||||
3-Year FCF Growth Rate | 41.4 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 28.69 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 54.92 | |||||
9-Day RSI | 47.14 | |||||
14-Day RSI | 44.53 | |||||
3-1 Month Momentum % | 0.02 | |||||
6-1 Month Momentum % | -24.91 | |||||
12-1 Month Momentum % | 20.91 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.19 | |||||
Quick Ratio | 1.17 | |||||
Cash Ratio | 0.86 | |||||
Days Inventory | 124.74 | |||||
Days Sales Outstanding | 1391.04 | |||||
Days Payable | 681.61 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -31.1 | |||||
Shareholder Yield % | -19.2 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 46.31 | |||||
Operating Margin % | -1068.68 | |||||
Net Margin % | -1124.81 | |||||
EBITDA Margin % | -1041.83 | |||||
FCF Margin % | -460.81 | |||||
OCF Margin % | -442.71 | |||||
ROA % | -60.18 | |||||
ROIC % | -72.1 | |||||
3-Year ROIIC % | 631.97 | |||||
ROC (Joel Greenblatt) % | -504 | |||||
ROCE % | -216.57 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 25.47 | |||||
PS Ratio | 50.96 | |||||
PB Ratio | 55.66 | |||||
Price-to-Tangible-Book | 52.4 | |||||
EV-to-EBIT | -4.74 | |||||
EV-to-EBITDA | -4.9 | |||||
EV-to-Revenue | 51.04 | |||||
EV-to-Forward-Revenue | 3.7 | |||||
EV-to-FCF | -11.08 | |||||
Price-to-GF-Value | 4.66 | |||||
Price-to-Median-PS-Value | 5.24 | |||||
Earnings Yield (Greenblatt) % | -21.1 | |||||
FCF Yield % | -8.13 |
Adocia Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Adocia Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Adocia
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers